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INTRODUCTION
Liver fibrosis and end stage liver cirrhosis are worldwide
healthcare problems (1). Hepatic fibrosis is a major histopatho-
logical finding associated with liver diseases due to ethanol,
viral infection, cholestasis, and metabolic disorders (2). Hep-
atic stellate cells (HSCs) play a crucial role in liver fibrosis,
including extensive remodeling of the extracellular matrix
(ECM) and deposition of fibrillar collagens type I and III (3).
HSCs are a major source of ECM proteins in the liver. Follow-
ing liver injury, HSCs are activated and increase the expres-
sion of matrix metalloproteinases (MMPs) and tissue inhi-
bitors of metalloproteinases (TIMPs) (3, 4). 
MMPs, a multi-domain family of zinc-dependent endopep-
tidases, degrade the structural components of the ECM and
many bioactive molecules (5). The MMP family is divided
into secreted and membrane-anchored enzymes. MMPs are
synthesized in a latent form and then converted into the extra-
cellularactive form via cleavage of specific conserved sequences. 
The membrane-type MMPs (MT-MMPs) are major medi-
ators of pericellular proteolysis. Gelatinase A, MMP-2, can
degrade denatured interstitial collagens (gelatins), type V col-
lagen, and intact type IV collagen, which are the major com-
ponents of basement membranes (4, 6). MMP-2 is activated
by MT1-MMP and/or plasmin (7). The mechanism of acti-
vation involves TIMP-2 interaction with MT1-MMP to form
a receptor complex that regulates the activation of MMP-2
(8-11). MMP-13, the interstitial collagenase in rodents, is a
specific protease capable of degrading fibrillar collagen (3). 
During hepatic fibrogenesis, MMPs involved in fibrillar
collagen degradation are down-regulated, whereas the expres-
sion of MMP-2 is markedly increased (12). However, this
enzyme activity is regulated by powerful inhibitors, TIMP-
1 and TIMP-2. TIMPs are secreted proteins that complex
with MMPs to modulate activity and activation (5). Hepat-
ic fibrosis arises when TIMPs inhibit ECM degradation exces-
sively (13). TIMP-1 controls most MMP activity, whereas
TIMP-2 inhibits MMP-2 by both inhibiting activity and
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Differential Expression of Matrix Metalloproteinases and Tissue
Inhibitors of Metalloproteinases in Thioacetamide-Induced Chronic
Liver Injury
Hepatic fibrogenesis, a complex process that involves a marked accumulation of
extracellular matrix components, activation of cells capable of producing matrix mate-
rials, cytokine release, and tissue remodeling, is regulated by matrix metallopro-
teinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The MMP-
TIMP balance can regulate liver fibrogenesis. The aim of this study was to evalu-
ate the expression patterns of MMPs and TIMPs during thioacetamide (TAA)-induced
liver fibrogenesis. Chronic liver injury was induced with TAA (200 mg/kg i.p.) for 4
or 7 weeks in male Sprague-Dawley rats. Hepatic injury and fibrosis were assessed
by hematoxylin-eosin (H&E) staining, and collagen deposition was confirmed by
Sirius Red staining. The level of hepatic injury was quantified by serological analy-
sis. The transcriptional and translational levels of a-smooth muscle actin (a-SMA),
MMPs, and TIMPs in the liver were measured by Western blotting, RT-PCR, and
immunohistochemistry. MMP, TIMP, and a-SMA were observed along fibrotic septa
and portal spaces around the lobules. TAA treatment increased transcription of both
MMPs and TIMPs, but only TIMPs showed increased translation. The dominant
expression of TIMPs may regulate the function of MMPs to maintain liver fibrosis
induced by TAA. 
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preventing the formation of active enzymes (14). We exam-
ined the expression patterns of MMPs and TIMPs in thioac-
etamide (TAA)-induced hepatic fibrosis animal model. 
MATERIALS AND METHODS
Animals
The experimental protocol was reviewed and approved by
the Institute Laboratory Animal Resources (ILAR) of Seoul
National University. Male Sprague-Dawley rats (body weight
100±30 g) were purchased from Orient Co. Ldt. (Seong-
nam, Korea). Rats were housed in the animal facilities of
Seoul National University College of Medicine and handled
following the guidelines for the care and use of laboratory
animals. Liver fibrosis was induced in rats by intraperitoneal
administration of TAA (Sigma, St. Louis, MO, USA), 200
mg/kg three times weekly for 4 or 7 weeks. Four groups con-
taining 10 rats each were treated as follows (Fig. 1): group
1, TAA for 4 weeks; group 2, saline for 4 weeks; group 3,
TAA for 7 weeks; group 4, saline for 7 weeks. Blood and liver
specimens were collected after sacrifice under ether anesthe-
sia. Some liver samples were fixed in formalin for histologi-
cal analysis, and some liver tissue was rapidly frozen in liq-
uid nitrogen and stored at -80℃ for the analysis of proteins
and mRNAs. 
Histological analysis
Liver tissues were fixed in 10% neutral buffered formalin
solution for 24 hr and embedded in paraffin. Sections were
cut to 4 mm and stained with hematoxylin-eosin. To evalu-
ate collagen deposition, sections were stained with Sirius Red
(saturated picric acid containing 0.1% Direct Red and 0.1%
Fast Green FCF, Sigma). The degree of fibrosis was assessed
by Scheuer’s scoring system as follows: grade 0, no fibrosis;
grade 1, portal fibrosis; grade 2, periportal fibrosis; grade 3,
septal fibrosis; grade 4, cirrhosis (15). 
Immunohistochemistry
Paraffin-embedded, formalin-fixed sections were baked at
65℃ for 90 min for deparaffinization, and then were rehy-
drated prior to antigen retrieval using a standard xylene/alco-
hol protocol. Endogenous peroxidase was inactivated by im-
mersing the slides for 30 min in a hydrogen peroxide solu-
tion. After a PBS rinse, the slides were placed in protein block-
ing agent (Zymed, South San Francisco, CA, USA) for 30 min.
The blocker was drained and the primary antibodies of MT1-
MMP (Oncogene, San Diego, CA, USA), MMP-2 (Oncogene),
MMP-13 (Oncogene and Chmicon, Temecula, CA, USA),
TIMP-1 (Calbiochem, San Diego, CA, USA), TIMP-2 (Onco-
gene and Chemicon), and a-smooth muscle actin (a-SMA;
Sigma, St. Louis, MO, USA) were then applied for 2 hr. Slides
were rinsed in PBS and biotinylated secondary antibodies
(Zymed, South San Francisco, CA, USA) were applied for
30 min. After rinsing with PBS, slides were incubated with
an avidin biotin complex (Zymed) for 30 min. Slides were
rinsed and incubated with DAB chromogen (Dako, Carpin-
teria, CA, USA) for 5 min. The reaction was stopped by rins-
ing in distilled water. All steps after the deparaffinization
were performed at room temperature.
Western blot analysis
Frozen liver tissue was homogenized and whole proteins
were extracted by ice-cold RIPA buffer (150 mM/L NaCl,
50 mM/L Tris-HCl, pH 7.4, 1 mM/L EDTA, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% SDS) with cocktail pro-
tease inhibitors (Roche, Mannheim, Germany). Protein con-
centration was measured by the BCA method (Pierce, Rock-
ford, IL, USA). The samples were heated at 100℃for 8 min,
and 50 mg proteins were separated on an SDS-polyacrylamide
gel. After electrophoresis, the proteins were electro-transferred
onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA).
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Fig. 1. Experimental Design. Animals were treated weekly intraperi-
toneal injections of TAA at 200 mg/kg (   ), which was replaced by
saline in untreated animals (   ). Total experimental period was 4 or
7 weeks. Rats were killed at the end of 4 or 7 weeks after the last
injection (   ).572 S.Y. Park, H.W. Shin, K.B. Lee, et al.
Membranes were blocked for 30 min with 5% skim milk
(BD, Sparks, MD, USA) in TBS-T. Afterward, membranes
were incubated with primary and HRP-conjugated secondary
antibodies, and then incubated with an enhanced chemilu-
minescent ECL assay kit (Pierce, Rockford, IL, USA) accord-
ing to the protocol provided by the manufacturer. Chemilu-
minescence was detected using Classic blue sensitive radio-
graphy film (Agfa, Belgium). 
Zymography 
Gelatin zymography was performed by following the man-
ufacturer’s instructions (Millipore, Billerica, MA, USA). Bri-
efly, protein extracts were prepared as above, except the heat
denaturing step, and then separated by electrophoresis through
a 7.5% SDS-polyacrylamide gel containing 1 mg/mL of gela-
tin. Gels were washed with 2.5% Triton X-100 for 30 min
2 or 3 times, followed by washing once with reaction buffer
containing 50 mM/L Tris-HCl (pH 7.5), 0.2 M/L NaCl, 5
mM/L CaCl2, and 0.02% Brij 35 to remove the SDS. Gels
were then incubated at 37℃for 16 hr in reaction buffer. The
gels were then stained with 0.5% Coomassie Blue R-250
(Sigma, St. Louis, MO, USA) and de-stained with an appro-
priate Coomassie R-250 de-staining solution (50:10:40
methanol:acetic acid:water) (16). Clear zones indicate the
presence of gelatinase activity. 
RNA extraction and RT-PCR
Total RNA was extracted from frozen tissue using a total
RNA mini kit for tissue (RBC, Taipei, Taiwan), following
the protocols provided by manufacturer. First strand cDNA
was generated with M-MLV reverse transcriptase (Promega,
Madison, WI, USA) using random primers (Promega). PCR
amplification was done with rTaq (Takara, Shiga, Japan). Gene-
specific primers and the sizes of the expected PCR products
are listed in Table 1. Expression of b-actin was used as an inter-
nal control. 
Biochemical assay
The enzyme activities of glutamic-oxaloacetic transaminase
(GOT), glutamic-pyruvic transaminase (GPT), g-glutamyl-
transferase (GGT), albumin (Alb), and total billirubin (T-Bil)
were measured with an Olympus 560 analyzer (Olympus,
Tokyo, Japan) in DiNonA Inc., Seoul, Korea. 
Statistical analysis
Data are expressed as the mean±S.D. Statistical analysis
was performed by Student’s t test. A value of P<0.05 was con-
sidered significant.
RESULTS
Induction of hepatic fibrosis by TAA
TAA treated rats showed reduced weight gain (Fig. 2A;
Primer sequences specific for the indicated rats genes and the sizes of
the expected PCR products are shown. 
Rat gene Primer sequence
PCR product
size (bp)
b-Actin (+) 5′ AGCTGAGAGGGAAATCGTGCG 3′ 300
(-) 5′ AGCTGAGAGGGAAATCGTGCG 3′
TIMP-1 (+) 5′ ACAGCTTTCTGCAACTCG 3′ 300
(-) 5′ CTATAGGTCTTTACGAAGGCC 3′
TIMP-2 (+) 5′ GTTTTGCAATGCAGATGTAG 3′ 540
(-) 5′ ATGTCGAGAAACTCCTGCTT 3′
MMP-13 (+) 5′ TGACTATGCGTGGCTGGA 3′ 400
(-) 5′ GTCTTCCCCGTGTCCTCAAA 3′
MMP-2 (+ )5′ GATACCCCAAGCCACTG 3′ 300
(-) 5′ TCCAAACTTCACGCTCTT 3′
MT1-MMP (+) 5′ AGGGTTCCTGGCTCATGC 3′ 1,040
(-) 5′ ACAGCGGCCGCACTCACA 3′
a-SMA (+) 5′ GCTCCATCCTGGCTTCTCTA 3′ 100
(-) 5′ TAGAAGCATTTGCGGTGGAC 3′
Table 1. Primers used for RT-PCR
Values are expressed as mean±SD at two time points in each group.
*P<0.01, TAA untreated vs. TAA treated group; 
�
P<0.05, TAA treated group for 4 weeks vs. TAA treated group for 7 weeks.
GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; GGT, gamma glutamyl transpeptidase.
Total bilirubin
(mg/dL)
Albumin
(g/dL)
GGT (mL/L) GPT (mL/L) GOT (mL/L)
4 weeks
TAA (-) 165.7±19.6* 52.3±6.8* 0.7±0.5* 4.7±0.4* 0.1±0.0
TAA (+) 267.6±57.2 83.38±19.3 4.0±2.7 4.4±0.3 0.2±0.1
7 weeks
TAA (-) 153.5±51.3* 49.3±6.8* 10.8±1.9* 4.4±0.3* 0.2±0.1*
TAA (+) 455.7±142.7
� 170.8±39.9
� 8.0±3.2
� 3.8±0.5
� 0.3±0.1
�
Table 2. Change of liver function enzymes at week 4 and 7MMPs and TIMPs in TAA-Induced Liver Injury 573
250.67±25.78 g vs. 402.40±29.85 g, P<0.001). The TAA
treated rats also showed increased GOT and GPT levels, with
greater induction at 7 weeks than at 4 weeks. Serum T-Bil
and GGT were also higher, suggesting the presence of chole-
static hepatic damage. Serum albumin levels were decreased,
indicating impairment of liver synthesis activity (Table 2).
Grossly, TAA-treated rats showed hepatomegaly with dif-
fuse, multi-nodular features and a hard consistency, suggest-
ing cirrhotic changes. These features were more prominent
in the TAA treated rats for 7 weeks. The liver weight/body
weight ratio was significantly higher in the TAA treated group
than in the untreated group (Fig. 2B). These results indicate
that hepatic injury and fibrosis were successfully induced by
TAA treatment. 
Histological features and liver function 
TAA treatment for 4 weeks slightly widened the portal areas
and formed thin fibrous septa throughout the hepatic parenchy-
ma, with inflammatory cell infiltration composed of lympho-
Fig. 2. Growth curves and relative liver weight in TAA-treated rats. (A) Each group (n=10) was given repeated injection with TAA or saline
for 4 or 7 weeks, and body weights were measured every week. The graph shows the mean±SD of body weight. (B) Relative liver weight
was calculated by the ratio to body weight. TAA treatment significantly increases the liver/body weight ratio. Data are expressed as the
mean±SD, *P<0.05, TAA treated vs. untreated rats. 
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Fig. 3. Histologic features and collagen deposition of livers after 4
or 7 weeks TAA treatment. (A) TAA significantly induced hepatic
fibrosis, especially at week 7 (H&E, ×100). (B) Collagen deposi-
tion (red) is prominent in TAA treated rats (Sirius Red, ×100) at
week 4 and 7. (C) Fibrosis scores expressed as the average
grade±SD. *P<0.001, TAA treated vs. untreated rats. 574 S.Y. Park, H.W. Shin, K.B. Lee, et al.
cytes and plasma cells (Fig. 3A). The 7-week TAA group show-
ed bridging or septal fibrosis connecting portal areas and cen-
tral veins in a portal to portal, portal to central, and/or central
to central pattern. Regenerating hepatic nodules were also
observed. The amount of infiltrating inflammatory cells was
also increased. Sirius red stained collagen fibers were observed
in the septa (Fig. 3B). Striking collagen deposition was pre-
sent in the periportal areas and areas of bridging fibrosis in the
TAA treated group, whereas only mild inflammatory cell infil-
tration around the portal area was found in controls, with no
collagen deposition or fibrous septa formation. Semi-quantifi-
cation of collagen deposition in the hepatic parenchyma was
2.1±0.1 at 4 weeks and 3.7±0.5 at 7 weeks (P=0.001 and
P<0.001, respectively, vs. controls), with controls scoring 0,
and a higher fibrosis score after 7 weeks (P<0.001) (Fig. 3C).
MMPs and TIMPs protein expression
We first confirmed MMP-2 expression and activity with
zymography, which can discriminate between the pro and
active forms of MMP-2. TAA treatment increased gelatin
degradation by MMP-2 (Fig. 4A) and slightly increased MMP-
2 levels (Fig. 4B). TAA slightly increased MT1-MMP and
decreased MMP-13 levels, but not significantly. In contrast,
TIMPs were significantly up-regulated during TAA induced
fibrosis (Fig. 4B, C). 
MMPs and TIMPs mRNA 
Next, we examined mRNA levels of MMPs and TIMPs
with RT-PCR (Fig. 5). TAA treatment increased the expres-
sion of a-SMA, MT1-MMP, MMP-2, MMP-13, TIMP-1,
and TIMP-2 and produced sharp product bands, in contrast
to smeared bands in the controls. All mRNA levels did not
change further between 4 and 7 weeks except TIMP-2. 
Immunohistochemical patterns of MMPs, TIMPs and 
a-SMA
Cells stained for MT1-MMP, MMP-2, TIMP-1, TIMP-2,
and a-SMA were present in the portal area and around the
central vein after TAA treatment (Fig. 6). Stained cells were
round and scattered in mildly expanding portal areas, but
changed to stellate-like spindle shapes in fully developed fib-
rous septa. These cells were mostly located in the interface of
portal area and hepatic parenchyma and also positively stained
for a-SMA, suggesting advanced fibrosis (Fig. 6). On the con-
trary, a-SMA positive cells were rarely identified in the con-
trol group or early stage fibrosis in the portal area. The increased
cellular components in fibrous septa with progress of fibrosis
had myofibroblast features. Morphologic features of epithelial
A
B C
Fig. 4. Protein expressions of MMPs and TIMPs in TAA induced liver fibrosis. (A) MMP-2 activity is increased in TAA treated rats using
zymography. (B) Protein expression pattern for MT1-MMP, MMP-2, MMP-13, TIMP-1, and TIMP-2 in TAA treated rats at week 4 and 7. (C)
TIMP-1 and TIMP-2 protein levels are significantly increased in the TAA-treated group. b-tubulin was used as the internal standard. *P<
0.05, TAA treated vs. untreated rat. All data are representative of three or four experiments performed with each group. 
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Fig. 5. Expression of a-SMA, MT1-MMP, MMP-2, MMP-13, TIMP-
1, and TIMP-2 mRNA in TAA-induced liver fibrosis. TAA treatment
increases mRNA level for a-SMA, MMPs, and TIMPs. RT-PCR prod-
ucts were obtained with specific primers for each gene and b-actin
as described in Table 1. 
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cells such as hepatocytes and cholangiocytes were not observed. 
DISCUSSION
TAA, a selective hepatotoxin, can induce acute and chron-
ic hepatic injury (17-19). In the current study, we showed
that TAA injection induced hepatomegaly, reduced weight
gain, and produced abnormalities of serum hepatic enzymes,
and a grossly cirrhotic liver. Microscopically, TAA caused
changes ranging from mild portal fibrosis to fully develop-
ed cirrhotic changes. In addition to fibrosis, TAA treatment
increased necro-inflammatory injuries, as shown by abnor-
malities of the serologic hepatic enzymes and H&E sections
(Fig. 3, Table 2). 
In the fibrotic liver, an imbalance occurs between excess
synthesis and/or a decrease in the removal of extracellular
matrix (ECM) with consequent scarring (19). MMPs and
TIMPs are involved in matrix remodeling in physiological
and pathological processes. MMP activities are regulated by
TIMPs, which bind in substrate and tissue specific manners
to MMPs, blocking their proteolytic activity (19). MMPs
are synthesized and secreted, in most cases, as proenzymes
that are then activated by proteinases such as plasmin (20,
21). For example, pro-MMP-2 is activated by MT1-MMP
and/or plasmin, and pro-MMP-9 can be activated by MMP-
3 and plasmin. Because matrix turnover is tightly regulated,
activation of pro-MMPs to active MMPs is strictly controlled
by complex formation with TIMPs (20). MMPs are expressed
in HSCs or hepatocytes (22), whereas TIMP-1 and TIMP-2
are expressed only in HSCs (23). 
Cells positive for MMPs and TIMPs in the portal areas and
around the central vein also showed a-SMA expression, a sur-
rogate marker of activated HSC (Fig. 6), in agreement with
previous studies (8, 11). Therefore, HSC may provide the
major sources of MMPs and TIMPs. 
In addition, we investigated MMP-2 as another biomarker
in the development of liver fibrosis and cirrhosis. Although
we did not distinguish pro-forms and active-forms of MMP-
2 in our Western blot assays, we observed that TAA increased
MMP-2 activity in the zymography assay (Fig. 3), which sug-
gests MMP-2 could participate in responses to hepatic injury
or as an early reaction for liver fibrosis. 
Interestingly, TAA treatment increased MMPs mRNA
expression and caused sharp bands to be formed, in contrast
to smeared bands present in controls (Fig. 4). Since the inter-
nal control, b-actin, is clearly detected, this result is not due
to experimental errors, such as reverse transcription failures
or RNA degradation. This discrepancy between mRNAs and
protein levels suggest that MMPs may be altered after tran-
scription.
Despite increased MMPs expression in TAA-induced liver
fibrosis, acceleration of fibrosis was not achieved. We showed
that TIMPs mRNA and protein level dramatically increase,
while MMPs level increase modestly or remain relatively stat-
ic as well. Thus, overexpression of TIMPs inhibits the ECM-
degrading functions of MMPs may explain the establishment
and maintenance of liver fibrosis. We did not characterize
MMPs or TIMPs function or conversion from pro to active
forms, which may be confirmed in future studies.
Differential expression of both MMPs and TIMPs occurs
in fibrotic liver disease and hepatocellular carcinoma (2, 3,
11-13). The balance of MMPs and TIMPs is the key factor
for liver fibrogenesis. To this respect, our results demonstrate
that increased TIMP expression is more critical than MMPs
in TAA-induced fibrogenesis. Understanding the balance of
MMPs and TIMPs activity may identify the prevention strate-
gies for liver fibrosis. 
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